Psychopharmacology and Psychiatry Updates

In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up over time, what side effects persist, and why blood pressure monitoring now deserves a permanent spot on your checklist.
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.5 CME: Quick Take Vol. 85
Xanomeline-Trospium Long-Term: Does Efficacy and Safety Hold Up After One Year?

In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — why it happens, which medications carry the highest risk, and how to build a proactive ABC strategy using switching, metformin, and emerging GLP-1 agonists to protect your patients' metabolic health. 
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know
Antipsychotic-Induced Weight Gain: Prevention and Management

In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-resistant depression. Dr. Derick Vergne breaks down the clinical evidence, dosing, and the anti-inflammatory mechanisms that may explain why EPA outperforms DHA in easing stubborn depressive symptoms.
Faculty: Derick E. Vergne, M.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 0.75 CMEs: Quick Take Vol. 84
Eicosapentaenoic Acid: Effective as Adjunctive for TRD?

In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin Sevarino breaks down a practical algorithm for selecting between naltrexone, acamprosate, disulfiram, and other options, tailored to hepatic function, from early liver disease through decompensated cirrhosis.
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder
Alcohol Use Disorder Algorithm: Medication Selection Based on Liver Status

In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done?
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 84
GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management?